Our People

Tom Dubensky, PhD Scientific Advisor

Dr. Dubensky is the Chief Scientific Officer of Aduro Biotech. He has extensive experience developing cancer immunotherapies.

Prior to Aduro, Dr. Dubensky served as Chief Scientific Officer of Immune Design Corp., where he was responsible for overseeing the development of immune therapies based on proprietary molecularly defined adjuvants and dendritic-cell-targeting vaccine platforms. He was a co-founder and Chief Scientific Officer of Anza Therapeutics, Inc., a biotechnology company which was spun out from Cerus Corporation in 2007, and he served as the Vice President of Research at Cerus beginning in 2002. At Cerus and at Anza, he helped to develop vaccine platforms based on attenuated strains of Listeria monocytogenes, which now serves as one of the technology platforms at Aduro. Previously, Dr. Dubensky developed vaccine platforms based on alphaviruses, adenoviruses, retroviruses/lentiviruses and plasmid DNA in positions of increasing responsibility at Viagene Biotech, Inc., Chiron Corporation and Onyx Pharmaceuticals.

Dr. Dubensky has co-authored more than 60 scientific papers and is an inventor on more than 25 issued U.S. patents and multiple pending applications. Dr. Dubensky received his B.A. in Bacteriology and Immunology from the University of California, Berkeley; he earned his Ph.D. at the University of Colorado Health Sciences Center; and he was a post-doctoral fellow at Harvard Medical School in the Department of Pathology.

Back to All